Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma
Open Access
- 10 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 34 (5) , 2056-2067
Abstract
Background: Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health. Hypothesis/Objectives: We hypothesized that dogs with OSA could be treated safely by ex vivo activated T-cells that were generated by autologous cancer vaccination and supported by interleukin-2 (IL-2) treatment with survival more than twice that reported for amputation alone. Animals: Osteosarcoma-bearing dogs (n = 14) were enrolled in a single-arm prospective trial after complete staging before amputation. Four healthy dogs also were treated in a safety study. Methods: Autologous cancer cell vaccinations were administered intradermally and dogs underwent leukapheresis. Mononuclear cell products were stimulated ex vivo with a T-cell-activating agent. Activated product was transfused and 5 SC IL-2 injections were administered q48h. Dogs were monitored for metastasis by thoracic radiography every 3 months. Results: Autologous cancer cell vaccine and activated cellular therapy (ACT) products were successfully generated. Toxicity was minimal after premedicants were instituted before ACT. With premedication, all toxicities were grade I/II. Median disease-free interval for all dogs was 213 days. One dog developed cutaneous metastasis but then experienced spontaneous complete remission. Median survival time for all dogs was 415 days. Five dogs survived >730 days. Conclusions and Clinical Importance: This immunotherapy protocol without cytotoxic chemotherapy is safe and tolerable. Compared to historical amputation reports, survival was notably prolonged in this group of patients. Additional prospective studies are warranted to elucidate active immunologic mechanisms and further improve disease response and survival.Keywords
This publication has 58 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Prognostic factors in canine appendicular osteosarcoma – a meta-analysisBMC Veterinary Research, 2012
- Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapyScientific Reports, 2012
- Collection of Peripheral Blood CD34+ Progenitor Cells from Healthy Dogs and Dogs Diagnosed with Lymphoproliferative Diseases Using a Baxter-Fenwal CS-3000 Plus Blood Cell SeparatorJournal of Veterinary Internal Medicine, 2011
- Cortical Allograft and Endoprosthesis for Limb‐Sparing Surgery in Dogs with Distal Radial Osteosarcoma: A Prospective Clinical Comparison of Two Different Limb‐Sparing TechniquesVeterinary Surgery, 2006
- Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for OsteosarcomaAnnals of Surgical Oncology, 2005
- Sample size tables for exact single‐stage phase II designsStatistics in Medicine, 2001
- Amputation and Carboplatin for Treatment of Dogs With Osteosarcoma: 48 Cases (1991 to 1993)Journal of Veterinary Internal Medicine, 1996
- Comparative Aspects of OsteosarcomaClinical Orthopaedics and Related Research, 1991
- Primary and secondary bone tumours in the dogJournal of Small Animal Practice, 1977